Anti-Osteoprotegerin antibody [OPG-13] (ab2147)


  • Product name
    Anti-Osteoprotegerin antibody [OPG-13]
    See all Osteoprotegerin primary antibodies
  • Description
    Mouse monoclonal [OPG-13] to Osteoprotegerin
  • Tested applications
    Suitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide, corresponding to amino acids 21-39 of Human Osteoprotegerin.

  • General notes
    Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation. Sterile filtered and lyophilized from 2 mg/ml in 0.2 M phosphate buffer, 0.2 M NaCl, pH 7.2.



Our Abpromise guarantee covers the use of ab2147 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    ELISA: 1/100000 when antibody is at a concentration of 1 mg/ml.
    WB: Use at an assay dependant dilution.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
    • Tissue specificity
      Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
    • Involvement in disease
      Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
    • Sequence similarities
      Contains 2 death domains.
      Contains 4 TNFR-Cys repeats.
    • Post-translational
      N-glycosylated. Contains sialic acid residues.
      The N-terminus is blocked.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • MGC29565 antibody
      • OCIF antibody
      • OPG antibody
      • Osteoclastogenesis inhibitory factor antibody
      • Osteoprotegerin antibody
      • PDB5 antibody
      • TNF receptor superfamily member 11b antibody
      • TNFRSF 11B antibody
      • TNFRSF11B antibody
      • TR 1 antibody
      • TR1 antibody
      • TR11B_HUMAN antibody
      • Tumor necrosis factor receptor superfamily member 11B antibody
      see all

    References for Anti-Osteoprotegerin antibody [OPG-13] (ab2147)

    ab2147 has not yet been referenced specifically in any publications.

    Product Wall

    The product is monoclonal antibody against OPG peptide - against one epitope of the peptide. It is almost impossible for mouse to produce antibody against its own epitope. Also the sequences are different. However, we haven't tested it in mouse.

    I am afraid, our antibody is applicable only in Wesern Blotting. It is not likele to recognize OPG in formalin fixed tissue, because it is a monoclonal antibody and developed against short peptide, however, we didn't test it and don't intent to do so. ...

    Read More


    Sign up